DRMA (STOCKS)
Dermata Therapeutics, Inc. Common Stock
$1.329900
-0.050100 (-3.63%)
Prev close: $1.380000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Gerald T. Proehl
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $8.32M
- Employees
- 8
- P/E (TTM)
- -0.31
- P/B (TTM)
- 1.59
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
2
Strong Buy
4
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Jun 2026 (Q2)
|
$-0.74 | $-0.56 | -0.1790 | -31.91% |
|
Mar 2026 (Q1)
|
$-0.48 | $-0.54 | +0.0606 | +11.21% |
|
Dec 2025 (Q4)
|
$-1.52 | $-1.57 | +0.0508 | +3.23% |
|
Sep 2025 (Q3)
|
$-1.65 | $-1.62 | -0.0282 | -1.74% |
Financial Statements
| Revenues | $0.00 |
| Operating Expenses | $8.60M |
| Selling, General, and Administrative Expenses | $6.97M |
| Research and Development | $1.63M |
| Operating Income/Loss | -$8.60M |
| Income/Loss From Continuing Operations After Tax | -$8.37M |
| Income/Loss From Continuing Operations Before Tax | -$8.37M |
| Net Income/Loss | -$8.37M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$8.37M |
| Net Income/Loss Available To Common Stockholders, Basic | -$8.37M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$4.39 |
| Diluted Earnings Per Share | -$4.39 |
| Basic Average Shares | 8,975,698 |
| Diluted Average Shares | 8,975,698 |
| Assets | $5.32M |
| Current Assets | $5.16M |
| Noncurrent Assets | $164.70K |
| Liabilities | $1.83M |
| Current Liabilities | $1.83M |
| Accounts Payable | $1.12M |
| Wages | $342.50K |
| Other Current Liabilities | $370.86K |
| Noncurrent Liabilities | $0.00 |
| Equity | $3.49M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $3.49M |
| Liabilities And Equity | $5.32M |
| Net Cash Flow From Operating Activities | -$8.08M |
| Net Cash Flow From Operating Activities, Continuing | -$8.08M |
| Net Cash Flow From Investing Activities | $1.96M |
| Net Cash Flow From Investing Activities, Continuing | $1.96M |
| Net Cash Flow From Financing Activities | $6.08M |
| Net Cash Flow From Financing Activities, Continuing | $6.08M |
| Net Cash Flow | -$7.80M |
| Net Cash Flow, Continuing | -$7.80M |
| Comprehensive Income/Loss | -$8.37M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$8.37M |
| Other Comprehensive Income/Loss | $0.00 |